Search results
Lung cancer: Pre- and postsurgical immunotherapy may improve outcomes
Medical News Today· 3 days agoLung cancer is a major cause of all cancer-related deaths, with some treatment options involving...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 3 days agoAustin, TX, USA, May 21, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Non-Small-Cell Lung Cancer ...
Can This Well-Loved Herb Help Fight Malignancies?
Mercola· 1 day agoStudies2,3,4 also support the notion that this humble herb has anticancer effects, which should be good enough reason for you to include more of it in your diet. A study published ...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 16 hours agoPreliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such ...
OncoHost to Present Poster Demonstrating PROphet®'s Application in Multiple Cancer Indications at...
FOX21 Colorado Springs· 16 hours agoThe presentation will highlight the ability of the company's PROphet® platform to predict clinical benefit from immune checkpoint inhibitor (ICI)-based therapies across various cancer ...
Rutgers Cancer Institute and RWJBarnabas Health Se | Newswise
Newswise· 1 day agoClinicians and scientists from Rutgers Cancer Institute and RWJBarnabas Health will lead sessions...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 15 hours agoCHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T cells (Tregs) was observed and depletion was maintained
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
Zacks via Yahoo Finance· 2 days agoIn the past 30 days, the Zacks Consensus Estimate for Ligand’s 2024 and 2025 earnings per share has...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 16 hours ago- Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast to be held on Monday, June 3 at 8:00
Purple Biotech (NASDAQ:PPBT) Receives Buy Rating from HC Wainwright
ETF DAILY NEWS· 1 day agoPurple Biotech (NASDAQ:PPBT – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently ...
